• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

与检查点抑制剂相关的神经毒性：两例病例报告及文献综述

Neurotoxicities associated with checkpoint inhibitors: Two case reports and a review of the literature.

作者信息

Cordes Lisa M, Davarpanah Nicole N, Reoma Lauren B, Gasmi Billel, Quezado Martha, Khan Omar I, Nath Avindra, Apolo Andrea B

机构信息

Genitourinary Malignancies Branch National Cancer Institute National Institutes of Health Bethesda Maryland.

Office of Clinical Research Office of the Director National Institutes of Health Bethesda Maryland.

出版信息

Clin Case Rep. 2019 Nov 26;8(1):24-32. doi: 10.1002/ccr3.2534. eCollection 2020 Jan.

DOI:10.1002/ccr3.2534
PMID:31998480
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6982490/
Abstract

We report a case of nivolumab-induced delayed-onset aseptic meningitis and a case of limbic encephalitis and peripheral nerve palsy with toxicity relapse 6 months after initial presentation. The atypical presentations contribute to our knowledge of these rare events and reinforce the necessity for vigilant monitoring and a multidisciplinary treatment approach.

摘要

我们报告了一例由纳武单抗引起的迟发性无菌性脑膜炎病例，以及一例在初次出现症状6个月后出现毒性复发的边缘叶脑炎和周围神经麻痹病例。这些非典型表现丰富了我们对这些罕见事件的认识，并强化了进行密切监测和采取多学科治疗方法的必要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e394/6982490/c20c90bc1ea7/CCR3-8-24-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e394/6982490/655ff652ccfc/CCR3-8-24-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e394/6982490/c20c90bc1ea7/CCR3-8-24-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e394/6982490/655ff652ccfc/CCR3-8-24-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e394/6982490/c20c90bc1ea7/CCR3-8-24-g002.jpg

相似文献

1
Neurotoxicities associated with checkpoint inhibitors: Two case reports and a review of the literature.与检查点抑制剂相关的神经毒性：两例病例报告及文献综述
Clin Case Rep. 2019 Nov 26;8(1):24-32. doi: 10.1002/ccr3.2534. eCollection 2020 Jan.
2
Immune checkpoint inhibitor-induced aseptic meningitis and encephalitis: a case-series and narrative review.免疫检查点抑制剂诱发的无菌性脑膜炎和脑炎：病例系列及叙述性综述
Ther Adv Drug Saf. 2021 Mar 29;12:20420986211004745. doi: 10.1177/20420986211004745. eCollection 2021.
3
Neurotoxicities associated with immune checkpoint inhibitor therapy.与免疫检查点抑制剂治疗相关的神经毒性。
J Neurooncol. 2021 Apr;152(2):265-277. doi: 10.1007/s11060-021-03695-w. Epub 2021 Jan 17.
4
Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.纳武单抗联合伊匹单抗或单独使用纳武单抗治疗晚期黑色素瘤相关的神经系统严重不良事件，包括一组脑炎病例
Oncologist. 2017 Jun;22(6):709-718. doi: 10.1634/theoncologist.2016-0487. Epub 2017 May 11.
5
Case Report: A Variety of Immune-Related Adverse Events Triggered by Immune Checkpoint Inhibitors in a Subject With Malignant Melanoma: Destructive Thyroiditis, Aseptic Meningitis and Isolated ACTH Deficiency.病例报告：恶性黑色素瘤患者使用免疫检查点抑制剂引发的多种免疫相关不良事件：破坏性甲状腺炎、无菌性脑膜炎和孤立性 ACTH 缺乏症。
Front Endocrinol (Lausanne). 2021 Oct 12;12:722586. doi: 10.3389/fendo.2021.722586. eCollection 2021.
6
Immune Checkpoint Inhibitor Induced Pericarditis and Encephalitis in a Patient Treated With Ipilimumab and Nivolumab for Metastatic Melanoma: A Case Report and Review of the Literature.免疫检查点抑制剂诱发的心包炎和脑炎在一名接受伊匹单抗和纳武单抗治疗转移性黑色素瘤的患者中发生：一例病例报告及文献综述
Front Oncol. 2021 Dec 9;11:749834. doi: 10.3389/fonc.2021.749834. eCollection 2021.
7
Fulminant Type 1 Diabetes Mellitus Developed about Half a Year after Discontinuation of Immune Checkpoint Inhibitor Combination Therapy with Nivolumab and Ipilimumab: A Case Report.纳武利尤单抗和伊匹单抗免疫检查点抑制剂联合治疗停药半年后发生暴发性 1 型糖尿病：1 例报告
Tohoku J Exp Med. 2021 Aug;254(4):253-256. doi: 10.1620/tjem.254.253.
8
Encephalitis Induced by Immune Checkpoint Inhibitors: A Systematic Review.免疫检查点抑制剂相关脑炎：系统评价。
JAMA Neurol. 2021 Jul 1;78(7):864-873. doi: 10.1001/jamaneurol.2021.0249.
9
Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy.免疫检查点抑制剂治疗后并发神经结节病的迟发性发作。
J Immunother Cancer. 2018 Jul 31;6(1):77. doi: 10.1186/s40425-018-0390-2.
10
Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy-Review of the Literature and Future Outlook.与纳武单抗、伊匹单抗和帕博利珠单抗治疗相关的神经免疫相关不良事件——文献综述与未来展望
J Clin Med. 2019 Oct 24;8(11):1777. doi: 10.3390/jcm8111777.

引用本文的文献

1
Immune checkpoint inhibitors-associated cranial nerves involvement: a systematic literature review on 136 patients.免疫检查点抑制剂相关的颅神经受累：对136例患者的系统文献综述
J Neurol. 2024 Oct;271(10):6514-6525. doi: 10.1007/s00415-024-12660-2. Epub 2024 Sep 3.
2
Long-term nivolumab treatment possibly associated with aseptic meningitis.长期使用纳武利尤单抗治疗可能与无菌性脑膜炎相关。
BMJ Case Rep. 2024 Feb 17;17(2):e258141. doi: 10.1136/bcr-2023-258141.
3
Pembrolizumab-induced aseptic meningitis in a patient with non-small cell lung cancer: A case report and literature review of aseptic meningitis as an immune-related adverse event.

本文引用的文献

1
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.免疫检查点抑制剂治疗患者免疫相关不良反应的管理：美国临床肿瘤学会临床实践指南。
J Clin Oncol. 2018 Jun 10;36(17):1714-1768. doi: 10.1200/JCO.2017.77.6385. Epub 2018 Feb 14.
2
Neurologic complications of immune checkpoint inhibitors.免疫检查点抑制剂的神经并发症。
J Neurooncol. 2018 May;137(3):601-609. doi: 10.1007/s11060-018-2752-5. Epub 2018 Jan 13.
3
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial.
帕博利珠单抗诱发非小细胞肺癌患者无菌性脑膜炎：一例病例报告及作为免疫相关不良事件的无菌性脑膜炎文献综述
Mol Clin Oncol. 2022 Jun 1;17(1):120. doi: 10.3892/mco.2022.2553. eCollection 2022 Jul.
4
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.癌症免疫治疗学会（SITC）免疫检查点抑制剂相关不良反应临床实践指南。
J Immunother Cancer. 2021 Jun;9(6). doi: 10.1136/jitc-2021-002435.
5
A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors.癌症免疫疗法毒性综述：免疫检查点抑制剂。
J Med Toxicol. 2021 Oct;17(4):411-424. doi: 10.1007/s13181-021-00833-8. Epub 2021 Apr 7.
6
Immune Checkpoint Inhibitors and Neurotoxicity.免疫检查点抑制剂和神经毒性。
Curr Neuropharmacol. 2021;19(8):1246-1263. doi: 10.2174/1570159X19666201230151224.
阿维鲁单抗治疗铂类治疗失败后的转移性尿路上皮癌（JAVELIN Solid Tumor）：一项开放标签、1 期试验两个扩展队列的汇总结果。
Lancet Oncol. 2018 Jan;19(1):51-64. doi: 10.1016/S1470-2045(17)30900-2. Epub 2017 Dec 5.
4
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.管理免疫检查点抑制剂相关毒性：癌症免疫治疗学会（SITC）毒性管理工作组的共识建议。
J Immunother Cancer. 2017 Nov 21;5(1):95. doi: 10.1186/s40425-017-0300-z.
5
Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.帕博利珠单抗对比化疗用于晚期 PD-L1 阳性 NSCLC 的疗效及安全性（KEYNOTE-024）：一项多中心、国际、随机、开放标签的 3 期临床试验。
Lancet Oncol. 2017 Dec;18(12):1600-1609. doi: 10.1016/S1470-2045(17)30690-3. Epub 2017 Nov 9.
6
Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials.并非所有免疫检查点抑制剂都一样：癌症试验中免疫相关不良事件的荟萃分析和系统评价。
Crit Rev Oncol Hematol. 2017 Nov;119:1-12. doi: 10.1016/j.critrevonc.2017.09.002. Epub 2017 Sep 8.
7
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer.免疫相关不良反应与纳武利尤单抗治疗非小细胞肺癌疗效的相关性。
JAMA Oncol. 2018 Mar 1;4(3):374-378. doi: 10.1001/jamaoncol.2017.2925.
8
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.一线帕博利珠单抗治疗铂类药物治疗禁忌的局部晚期和不可切除或转移性尿路上皮癌患者（KEYNOTE-052）：一项多中心、单臂、2 期研究。
Lancet Oncol. 2017 Nov;18(11):1483-1492. doi: 10.1016/S1470-2045(17)30616-2. Epub 2017 Sep 26.
9
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.免疫疗法毒性管理：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2017 Jul 1;28(suppl_4):iv119-iv142. doi: 10.1093/annonc/mdx225.
10
Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) Antibodies.与抗程序性死亡1（PD-1）抗体相关的神经并发症
JAMA Neurol. 2017 Oct 1;74(10):1216-1222. doi: 10.1001/jamaneurol.2017.1912.